Clinically compatible cell culture system to generate endothelial cells (EC) from human pluripotent stem cells (hPSC).
- Produces hPSC-ECs in high yield.
- Compatible with clinical applications of hPSC-derived endothelial cells.
- Engrafted cells survive longer (>10 months) than in prior published research (weeks).
According to the World Health Organization (WHO), cardiovascular diseases (CVD) are the most common causes of death globally. CVDs such as coronary heart disease, cerebrovascular disease, and peripheral arterial disease can cause loss of vascular supply, or ischemia. Ischemia causes loss of oxygen needed for cell function and leads to cell dysfunction and cell death. Therapies that promote growth of blood vessels are necessary to mitigate ischemic damage. Human pluripotent stem cells (hPSC) are a promising source for generating endothelial cells (EC), which play a crucial role in blood vessel growth and function.
hPSC-derived endothelial cell (EC) therapies are limited by the need for a clinically compatible system that is free of xenogeneic components, has high functional EC yield, can be verified in multiple cell lines, and has no tumorigenic potential. Emory inventors developed a cell culture system to generate purified, functional EC with pro-angiogenic properties. These cells express EC factors CDH5, Von Willebrand factor, and KDR. Engineered EC also produce nitric oxide and form vascular-like structures. This cell culture system was found to increases EC marker expression in three human embryonic stem cell (hESC) lines and in two human induced pluripotent stem cell (hiPSC) lines. When injected into mice, hPSC-derived EC incorporated into blood vessels over time and were not found to form tumors.
This system has been tested in vitro and in vivo.
Publications: Lee, S. et. al. (2017). Circulation,136(20), 1939-1954.